The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.
Study authors reported on the 1-year safety and efficacy of guselkumab treatment in patients with active psoriatic arthritis.
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
Study authors compared the effect of upadacitinib vs placebo and adalimumab on pain in patients with active psoriatic arthritis.
Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.
Survival and discontinuation rates of infliximab when treating psoriasis in real world conditions were analyzed.
Researchers evaluated the association between fibromyalgia in psoriatic arthritis and enthesopathy, sleep, fatigue, and quality of life.
Researchers evaluated the performance of carotid ultrasound in distinguishing between patients with psoriatic arthritis with and without coronary artery disease.
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
A case report of a patient with 20-year, unstable psoriasis who presented with new erthroderma and subsequent treatment with systemic corticosteroids and methotrexate.